221 related articles for article (PubMed ID: 12565965)
1. Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.
Ananthan S; Kezar HS; Saini SK; Khare NK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem Lett; 2003 Feb; 13(3):529-32. PubMed ID: 12565965
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
3. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
[TBL] [Abstract][Full Text] [Related]
4. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
[TBL] [Abstract][Full Text] [Related]
5. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
6. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
J Med Chem; 1998 Dec; 41(25):4911-4. PubMed ID: 9836606
[No Abstract] [Full Text] [Related]
7. delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole.
Coop A; Rothman RB; Dersch C; Partilla J; Porreca F; Davis P; Jacobson AE; Rice KC
J Med Chem; 1999 May; 42(9):1673-9. PubMed ID: 10229636
[TBL] [Abstract][Full Text] [Related]
8. The selectivity of the opioid antagonist, naltrindole, for delta-opioid receptors.
Rogers H; Hayes AG; Birch PJ; Traynor JR; Lawrence AJ
J Pharm Pharmacol; 1990 May; 42(5):358-9. PubMed ID: 1976787
[TBL] [Abstract][Full Text] [Related]
9. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
Broom DC; Guo L; Coop A; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):1195-200. PubMed ID: 10945877
[TBL] [Abstract][Full Text] [Related]
10. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
[TBL] [Abstract][Full Text] [Related]
12. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
[TBL] [Abstract][Full Text] [Related]
14. Diprenorphine has agonist activity at opioid kappa-receptors in the myenteric plexus of the guinea-pig ileum.
Traynor JR; Corbett AD; Kosterlitz HW
Eur J Pharmacol; 1987 May; 137(1):85-9. PubMed ID: 3038579
[TBL] [Abstract][Full Text] [Related]
15. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist.
Portoghese PS; Sultana M; Takemori AE
Eur J Pharmacol; 1988 Jan; 146(1):185-6. PubMed ID: 2832195
[No Abstract] [Full Text] [Related]
16. Synthesis of 7-arylmorphinans. Probing the "address" requirements for selectivity at opioid delta receptors.
Gao P; Larson DL; Portoghese PS
J Med Chem; 1998 Jul; 41(16):3091-8. PubMed ID: 9685249
[TBL] [Abstract][Full Text] [Related]
17. N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.
Thomas JB; Zheng X; Mascarella SW; Rothman RB; Dersch CM; Partilla JS; Flippen-Anderson JL; George CF; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 Oct; 41(21):4143-9. PubMed ID: 9767649
[TBL] [Abstract][Full Text] [Related]
18. (-)-N,N'-but-2-ene-1,4-diylbimorphinans.
Schmidhammer H; Smith CF; Dalkner E; Erlach D; Heuberger M; Rollinger JM
Pharmazie; 1991 Feb; 46(2):101-2. PubMed ID: 1649476
[TBL] [Abstract][Full Text] [Related]
19. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 14-alkoxymorphinans. 17. Highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans.
Schütz J; Dersch CM; Horel R; Spetea M; Koch M; Meditz R; Greiner E; Rothman RB; Schmidhammer H
J Med Chem; 2002 Nov; 45(24):5378-83. PubMed ID: 12431065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
